Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis

Journal of Neurosurgical Sciences

Volumn 55, Issue 1, 2011, Pages 1-6

  Salvati, M ^a,b   D'Elia, A ^b   Frati, A ^a,b   Brogna, C ^b   Santoro, A ^b   Delfini, R ^b  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chemotherapy, adjuvant; Diagnosis; Glioblastoma

Indexed keywords

CARMUSTINE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GLIOMA; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOCOMPATIBLE MATERIALS; CARMUSTINE; COMBINED MODALITY THERAPY; DECANOIC ACIDS; DRUG DELIVERY SYSTEMS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POLYESTERS; SUPRATENTORIAL NEOPLASMS; SURVIVAL RATE;

EID: 79959707321     PISSN: 00264881     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345:1008-12.
2. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-7. (Pubitemid 28450038)
3. De Angelis LM, Burger PC, Green SB, Cairncross JG. Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol 1998,44:691-5.
4. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Metaanalysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-97. (Pubitemid 23100496)
5. Gururangan S, Cokgor I, Rich JN, Edwards S, Affronti ML, Quinn JA et al. Phase I study of Gliadel™ wafers plus temozolomide in adults with recurrent supratentorial high grade gliomas. NeuroOncol 2001;240:246-50.
6. Limentani SA, Asher A, Heafner M, Kim JW, Fraser R. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neurooncol 2005;72:241-4. (Pubitemid 40867407)
7. Newlands ES, Stevens MFS, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of ist discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61. (Pubitemid 27273454)
8. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005;109:93-108. (Pubitemid 40287792)
9. Stewart LA, and Glioma Meta-analysis Trialists (GMT) group: Chemotherapy in adulthigh grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002;359:1011-8. (Pubitemid 34286538)
10. Stupp R, Hegi M, Van den Bent M, Mason W, Weller M, Mirimanoff R et al. on behalf on the European Organization for Research and Treatment on Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group: Changing paradigms - an update on the multidisciplinary management of malignant glioma. The Oncologist 2006;11:165-180.
11. Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M et al. Rariotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 2005;352.987-96.
12. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O et al Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997;41:44-8.
13. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC et al. A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003;5:79-88. (Pubitemid 36422560)
14. Pan E, Mitchell S, Tsai J. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol 2008;88:353-7.
15. McGirt M, Than K, Weingart J, Chaichana K, Attenello F, Olivi A et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009;110:583-8.
16. McGirt M, Brem H. Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy. Ann Surg Oncol 2010;17:1729-31.